



**About:** Melcap specializes in the development and design proprietary and innovative non-invasive Wireless Ingestible Capsule Systems for the treatment of Obesity and Overweight.

**Stage:** Round A, Clinical

**Industry:** Medical – Obesity and Overweight ( BMI : from 27 to 35 and more).

**Market Size:** +\$250B

**Employees:** 11

**Patents:** Granted in the US and Israel, three pending PCT applications, one pending application in the US.

**Funding to-Date:** \$3M

**Required Funding:** \$1.7M

#### Use of Proceeds:

- i. Pivotal multi-center human clinical study for ODC System
- ii. First in the Human clinical study for LGR capsule System
- iii. Application for CE mark approval for ODC system

#### Contact Information:

Dr. Alex Melamud, CEO  
+972-54-67-996-03  
[alexm@melcap-systems.com](mailto:alexm@melcap-systems.com)

#### Address:

MATAM, Bld.15, POB 15145,  
HAIFA, 31905,Israel

#### Company website:



<http://www.melcap-systems.com/>

## Products

Melcap Non-invasive Wireless Ingestible Capsule Systems comprise Disposable Capsule, reusable Wearable wrist or chest band , and Capsule activator. Medical paradigm is based on proved Mechanism of Gastric Electrical Stimulation (GES) of internal parts of GI tract. Wireless remote control is based on Android or IOS Smartphones, where Melcap proprietary Mobile Application is installed.

Melcap develops two System Products:

1. One day Capsule (ODC) System
2. Long Gastric Retention (LGR) System, which retains in the patient stomach for up to 30 days. LGR capsule is a first-of-its-kind ingestible, non- invasive capsule system for the treatment of obesity and overweight with ultra-long gastric retention time in the stomach.



## Current Status

Currently, the Company completed Animal Trials, passed Biocompatibility and Safety tests and got approval from EC of Israel Hospital and **Israeli Ministry of Health** to conduct First in Human (FIH) Clinical Trials.

## Purposes and Benefits

- i. **Suppresses appetite, giving a feeling of fullness/satiety by using Melcap's novel electrical stimulation paradigm based on two mechanisms: Neuromodulation and Pacing.**
- ii. Disposable, chemicals free and safe.
- iii. Does not require surgery and implantation.
- iv. Provides patient-tailored treatment which fits individual meal schedule.
- v. Allows patient biofeedback-based product design.

## Management Team

### Dr. Alex Melamud, CEO

Holds Ph.D. in Physics, 25 years experience in the field of the medical devices research, development and clinical trials.

### Mr. Boris Voznesensky, CTO

Holds BSc. Electronics, 30 years Experience in design of electrostimulation systems.

### Mr. Josef More, CFO, BD

Economist, 35 years in medical devices start-ups management.

### Prof. Yehuda Ringel, MD, Medical Director

Chief, Division of Gastroenterology and Hepatology, Meir Medical Center, Israel; Adjunct Professor of Medicine Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, USA